PTSD Trial, Recruiting NCT07115030 Sponsor: Yale University Condition: PTSD
Back to Ptsd

PTSD Trial, Recruiting

NCT07115030
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Women aged 18 or older
  • People currently receiving medication treatment for opioid use disorder (MOUD) at one of the participating clinics
  • People who have been on this medication treatment for more than 14 days
  • People who started their current treatment episode within the last 12 months
  • People who have experienced physical or emotional abuse from an intimate partner at some point in their life
  • People whose PTSD symptoms are causing at least a moderate level of difficulty in day-to-day functioning, as measured by a specific assessment tool (the B-IPF)
  • People who are available during the scheduled times for the group sessions
  • People who are able to read and understand English
  • People who are able to give written consent to participate

Who may not be able to join:

  • People who do not pass a questionnaire designed to check whether they can give informed consent
  • People with an unstable medical condition (such as a recent hospitalisation, upcoming surgery, newly started chemotherapy, or palliative care) or an unstable mental health condition (such as untreated psychosis) that could make it difficult to take part
  • People who will be unavailable for more than four weeks in a row during the study (for example, due to a planned move or surgery)
  • People who are unable to read or understand English
  • People who are unable to provide at least one way for the trial team to contact them

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 22 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Tami Sullivan, PhD, Yale University

Phone: 203-789-7645

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Registry
ClinicalTrials.gov
Start date
1 June 2026
Est. completion
31 August 2029

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Retention in MOUD treatment

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov